The in vitro bactericidal activity of cefazolin was found to be similar to that of cephaloridine and cephalothin but slightly greater than that of cephalexin against a majority of 233 strains of gram-positive and gram-negative organisms. Cefazolin, however, was two-to eightfold more active than the other two drugs against Escherichia coli and klebsiella. The mean peak concentrations in the serum in 10 normal subjects 1 h after intramuscular injections of 1,000, 500, and 250 mg of cefazolin were 38.8, 18.6, and 12.2 ,g/ml, respectively. The antibiotic could still be detected at 8 h. Peak values for a given dose of cephaloridine were comparable. However, blood levels of cefazolin were regularly higher than those of cephaloridine over the first 8 h. The mean half-life of cefazolin in the serum was 2 h, whereas that of cephaloridine was 1.4 h. The degree of serum protein-binding was strikingly higher for cefazolin (81%) than for cephaloridine (24%), suggesting that the antibacterial activity of the former in serum might be less than that of cephaloridine after equal doses. This proved to be the case when the bacterial activity of blood drawn 1, 4, and 8 h after injection of the two drugs was examined.
Cefazolin (SKF-41558-Z) is a derivative of cephalosporin C (3, 4) . Its structure differs substantially from that of cephalothin, cephalexin, and cephaloridine. The antibacterial activity of cefazolin has been reported to be similar or somewhat inferior to that of the other cephalosporin derivatives against gram-positive bacteria, and moderately better against Escherichia coli and klebsiella (10, 12, 13) .
Animal studies have indicated that cefazolin is less nephrotoxic and is excreted in bile in higher concentration than is cephaloridine (11, 12) . Cefazolin undergoes no appreciable degree of biotransformation after parenteral administration (3, 6) . Intramuscular injection of this agent in man results in sustained levels in the serum, and high concentrations appear in the bile (15) . Protein-binding is more extensive than with any of the other cephalosporins (12) .
The purposes of the present study were (i) to compare the in vitro antibacterial activity of cefazolin with that of cephaloridine, cephalexin, and cephalothin; (ii) to evaluate the effect of protein-binding on activity in vitro and in vivo; and (iii) to study the pharmacology of cefazolin and cephaloridine in normal volunteers.
MATERIALS AND METHODS
In vitro antibacterial activity. Serial twofold dilutions of each antibiotic were made by using a 96-channel automatic pipette and diluter (0.05 ml) and plastic disposable plates (Cooke Engineering Co.). Seventy strains of gram-positive and 163 strains of gram-negative bacteria were studied. An overnight growth of each organism was diluted to yield 101 bacteria per ml; this inoculum was dispensed in 0.05-ml volumes by using a microdel (Cooke Engineering Co.). For most organisms, the medium used for diluting the organism and antibiotic was Trypticase soy broth (Difco). Todd Hewitt broth was used for studies of Diplococcus pneumoniae and Streptococcus pyogenes, and Leventhal broth was used for Hemophilus influenzae.
After inoculation, the plates were incubated at 37 C; candle jars were used for H. influenzae and S. pyogenes. Eighteen hours later, the plates were examined for the presence of growth at the bottom of the well. The minimal inhibitory concentration was the maximal dilution of antibiotic in which no growth was visible. Subculture on appropriate agar was then made from clear wells, and the maximal dilution yielding no growth was considered to be the minimal bactericidal concentration.
Effect of serum. The degree of serum protein-binding of four cephalosporins was determined by an equilibrium dialysis technique (9) . The initial concentration of antibiotic in either the serum or protein-free side of the chamber was 50 ,ug/ml.
The effect of serum on the in vitro antibacterial activity of cefazolin and cephaloridine was studied by using four gram-positive organisms. Serial dilutions were performed as in broth studies, except that the final medium in the well consisted of 90% pooled human serum and 10% double-strength broth.
Pharmacological studies. Ten healthy young male volunteers (average age 23 years) were studied. Complete blood count, urinalysis, and examination of liver and kidney function were carried out before and after cefazolin was administered. All candidates received an intramuscular injection of 1,000 or 500 mg of cefazolin or cephaloridine; nine were given 250 mg of cefazolin as well. Venous blood was drawn 0.5, 1, 2, 4, 6, and 8 h after injection of the antibiotic. Urine was collected during the first 2 h and 2 to 8 h after treatment. All specimens were frozen (-20 C) and assayed for antibiotic concentration within 5 days by an agar diffusion method using Bacillus subtilis (Bacto Spore Suspension, Difco) as the test organism. Standard curves for the antimicrobial assay of specimens of urine and serum were prepared by diluting the antibiotic in saline and pooled human serum, respectively.
The "area under the curve" of antibiotic in serum was calculated by a standard method (2) . The halflife of cefazolin and cephaloridine in the serum was computed by the Method of least squares (8 Table 3 ). The antibiotic was still detectable in the blood after 8 h in concentrations of 4.1, 2.5 and 0.9 ,ug/ml. Mean values after the administration of 1,000 and 500 mg of cephaloridine were 32.7 and 19.2 ug/ml at 1 h and 1.4 and 0.5 ug/ml at 8 h, respectively. There was little variation among individual subjects (Fig. 2, 3) .
The mean concentrations of cefazolin in the serum 4 to 8 h after injection were two-to fivefold higher than those of cephaloridine (Table 3) . Mean levels of free antibiotic, however, calculated from the data presented in Table 3 and from the protein-binding results, were strikingly higher for cephaloridine than for cefazolin during the first 4 h ( (Table 3) .
The "area under the curve" for cefazolin was 1.65 times greater than that for cephaloridine when both 1,000 and 500 mg were given. The difference between the two agents was highly significant (P <:0.001) by a paired t test. When these values were corrected for serum proteinbinding, however, the "area under the curve" of free cephaloridine 2.45 times greater than that of cefazolin at both dose levels.
Half-life of cefazolin. The mean and standard errors of the half-life of cefazolin were 2.02 + 0.13 and 2.02 4 0.11 h with the 1,000-and 500-mg doses, respectively. Comparable values for cephaloridine were 1.37 ± 0.11 and 1.08 + 0.08 h. The half-life of cefazolin was significantly longer than that of cephaloridine at both doses (P < 0.01).
Antibacterial activity in research subjects. The antibacterial activity of the serum after intramuscular injection of 500 mg of cefazolin or cephaloridine against penicillin-sensitive Sta- phylococcus aureus is shown in Fig. 4 . Bactericidal titers of cephaloridine were strikingly higher than those of cefazolin for both penicillin-sensitive and resistant strains of S. aureus at all intervals of time studied. Only one treated subject exhibited bactericidal activity at a dilution of 1: 4 against the penicillin-sensitive organism at 8 h. In contrast, the sera of all recipients of cephloridine were bactericidal at a dilution of 1:8 or higher at this time (Fig. 4) . Both D. pneumoniae and S. pyogenes were killed at serum dilutions of 1:32, 1:8, and 1:4 at 1, 4, and 8 h after the injection of 500 mg of cefazolin.
Pain tolerance. The degree of pain associated with the intramuscular injection of 500 or 1,000 mg of either cefazolin or cephaloridine dissolved in no less than 2 or 3 ml of water was compared, in double blind fashion, in nine subjects. Cefazolin appeared to be more painful in only one of these individuals; in the others, there was no difference in the degree of discomfort. This observation is in agreement with the results of another study (6) .
DISCUSSION
The in vitro data presented here indicate that the antibacterial activity of cefazolin against gram-positive and gram-negative organisms is similar to that of cephlothin and cephaloridine and somewhat greater than that of cephalexin. Cefazolin appears to be considerably more potent than the other cephalosporins or ampicillin against E. coli; this confirms previously published data (10, 15) . There is also an appreciable bactericidal effect against enterococci; this is in contrast to the observations of others (5, 14) .
The mean peak concentrations of cefazolin in serum were noted to be similar to those of cephaloridine after the administration of equal doses (14) . In contrast, the results of several other studies indicate markedly higher serum levels of cefazolin than of cephaloridine after exhibition of the same quantity of each drug (1, 12) . The explanation for the discrepancy is not clear, since serum concentrations of drugs rep- resent the results of many factors (7) . The half-life of cefazolin in serum was considerably longer than that of cephaloridine after intramuscular injections; thus, the "area under the curve" of the former was 1.6 times greater than that of the latter.
The degree of serum protein-binding of cefazolin (81%) was markedly higher than that of cephaloridine (24%). This is probably the reason for the striking reduction in the in vitro activity of cefazolin when serum, rather than broth, was used as diluent. Since only free drug appears to be bactericidal, the degree of protein-binding must be taken into account when circulating levels of antibiotics are compared (7) . In addition, studies in our laboratory suggest that the quantity of an antibiotic in subcutaneous fibrin loci is directly related to the peak concentrations of free antibiotic in the serum (unpublished data). The present studies indicated that maximal levels of free cephaloridine were several times higher than those of cefazolin. However, this does not necessarily imply that cephaloridine is preferable to cefazolin in clinical situations since concentrations in specific organs, such as liver and kidney, may exceed those in the blood. Furthermore, differences in the degree of nephrotoxicity (12) and in activity against specific pathogens may confer a significant advantage to cefazolin. 
